Koers Aequus Pharmaceuticals Inc Toronto S.E.
Aandelen
CA0076361033
Farmaceutische producten
Omzet 2022 | 1,38 mln. 1 mln. 939K | Omzet 2023 | 255K 185K 173K | Marktkapitalisatie | 3,32 mln. 2,41 mln. 2,26 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -3 mln. -2,18 mln. -2,04 mln. | Nettowinst (verlies) 2023 | -2 mln. -1,46 mln. -1,36 mln. | EV/omzet 2022 | 5,17 x |
Nettoschuld 2022 | 2,49 mln. 1,81 mln. 1,69 mln. | Nettoschuld 2023 | 4,89 mln. 3,56 mln. 3,33 mln. | EV/omzet 2023 | 32,2 x |
K/w-verhouding 2022 |
-1,45
x | K/w-verhouding 2023 |
-1,12
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 85,32% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anne Stevens
FOU | Founder | - | 01-01-13 |
Douglas Janzen
CEO | Chief Executive Officer | 56 | 03-01-13 |
Ann Fehr
DFI | Director of Finance/CFO | 55 | 22-07-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Douglas Janzen
CEO | Chief Executive Officer | 56 | 03-01-13 |
Marc Lustig
BRD | Director/Board Member | 51 | 15-02-21 |
Director/Board Member | 54 | 18-12-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+50,70% | 791 mld. | |
+41,96% | 630 mld. | |
-7,15% | 350 mld. | |
+18,77% | 328 mld. | |
+8,79% | 298 mld. | |
+18,02% | 246 mld. | |
+1,27% | 225 mld. | |
+11,95% | 218 mld. | |
+3,68% | 160 mld. |